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In this study we have used in situ hybridization with
radiolabeled antisense RNA probes to examine the
expression of mRNA for urokinase-type plasminogen
activator and its receptor in histologic samples of
squamous cell (n = 7) and basal cell (n = 7) carcino-
mas of the skin. Messenger RNA for both urokinase-
type plasminogen activator and its receptor were
expressed in all of the squamous cell carcinomas, but
could not be detected in the basal cell carcinomas.
In all of the seven squamous cell carcinomas a signal
for urokinase-type plasminogen activator receptor
mRNA was detected focally in well-differentiated
cancer cells surrounding keratinized pearls, and in
four specimens urokinase-type plasminogen activator
receptor mRNA was in addition expressed by cancer
cells at the edge of invasively growing strands of
tumor. Urokinase-type plasminogen activator
mRNA expression was found in virtually all the can-
cer cells of the squamous cell carcinomas, and
importantly we found, by hybridizations for uroki-
nase-type plasminogen activator and its receptor
mRNA on adjacent sections of squamous cell carci-
nomas, that it was exactly the invading cancer cells
that simultaneously expressed both these components
required for plasmin-mediated proteolysis at the cell
surface. We have previously shown that both uroki-
nase-type plasminogen activator and its receptor
mRNA are expressed by the leading-edge keratino-
cytes in regenerating epidermis during mouse skin
wound healing, and that wound healing is impaired
in mice made de®cient in plasminogen by targeted
gene disruption. We propose that there are similari-
ties between the mechanisms of generation and
regulation of extracellular proteolysis during skin re-
epithelialization and squamous cell carcinoma inva-
sion. The ability of the squamous carcinoma cells to
mimic the ``invasive'' phenotype of re-epithelializing
keratinocytes may be one of the factors that make
squamous cell carcinomas more aggressive tumors
than basal cell carcinomas. Key words: extracellular pro-
teolysis/plasminogen/skin carcinoma/uPA/uPAR/wound
healing. J Invest Dermatol 116:353±358, 2001
S
quamous cell carcinomas of the skin are generally well-
differentiated tumors with invasive in®ltrating growth
and a signi®cant potential for metastatic spread. Basal cell
carcinomas of the skin, on the other hand, are
characterized by a tendency to eroding growth and
virtually no metastatic capacity. This difference in aggressiveness
between the two skin malignancies has been related to the ability of
squamous cell carcinomas to generate extracellular proteolysis by
the urokinase-type plasminogen activator (uPA) pathway of
plasminogen activation (Sappino et al, 1991; Miller et al, 1992).
Elevated levels of uPA that may lead to excessive generation of
plasmin from plasminogen has been reported in several malig-
nancies (Danù et al, 1999; Mignatti and Rifkin, 1993). Plasmin can
potentially degrade many different proteins in the extracellular
matrix, and may also be involved in the activation of other matrix-
degrading proteases (Werb et al, 1977; Okumura et al, 1997) and
latent growth factors (Mignatti and Rifkin, 1993; Grainger et al,
1994). Increased activity of matrix-degrading proteases such as
plasmin and matrix metalloproteinases enables metastasizing cancer
cells to penetrate basement membranes and other barriers in the
extracellular matrix.
An important factor in the generation of plasmin-mediated
pericellular proteolysis is the binding of uPA to its speci®c cell surface
receptor (uPAR) (Danù et al, 1994; Vassalli, 1994). uPAR has been
identi®ed in vitro on the surface of many cell types of both normal and
malignant origin. It is a highly glycosylated 55±60 kDa single-
polypeptide-chain protein consisting of three domains. At the C-
terminus uPAR is attached to the cell membrane by a phosphatidyl-
inositol glycolipid anchor (Behrendt andStephens, 1998).Both active
uPA and its virtually inactive proenzyme (pro-uPA) bind to uPAR
with high af®nity. Pro-uPA can be activated to uPA by plasmin while
bound to uPAR, and receptor-bound uPA can activate plasminogen
(Blasi et al, 1987). Concomitant binding of pro-uPA and plasminogen
to cell surfaces strongly accelerates plasmin generation (Ellis et al,
1991), and surface-bound plasmin is protected from natural plasmin
inhibitors. Cell surfaces therefore appear to be preferential sites for the
urokinase pathway of plasminogen activation, requiring the con-
comitant expression of uPA and uPAR (Ellis et al, 1996). uPAR may
also have functions not directly related to plasminogen activation
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(Blasi, 1999), such as signal transduction following receptor
occupancy (Vassalli, 1994), as an adhesion receptor for vitronectin
(Wei et al, 1994; Hùyer-Hansen et al, 1997), and regulation of integrin
function (Wei et al, 1996).
In colon adenocarcinomas uPAR has been identi®ed in both
cancer cells and macrophages at invasive foci, whereas neighboring
®broblast-like cells express uPA (Grùndahl-Hansen et al, 1991;
Pyke et al, 1991, 1994). In ductal breast carcinomas uPAR is
located in tumor-associated macrophages (Pyke et al, 1993),
whereas uPA is expressed by myo®broblasts or in some rare cases
by the cancer cells (Danù et al, 1994; Nielsen et al, 1996; Johnsen
et al, 1998). These data indicate that in some types of cancer tumor-
associated stromal cells may be involved in the generation of
extracellular proteolysis during cancer cell invasion (Johnsen et al,
1998). These studies have also shown, however, that the distinctive
expression pattern of uPA and its receptor varies between different
types of cancer and re¯ects the expression during certain non-
neoplastic tissue remodeling processes in the tissue from which the
cancer originates. In order to elucidate the mechanism involved in
generation and regulation of plasmin-mediated extracellular
proteolysis in skin carcinomas, we have now studied the expression
of uPAR mRNA in squamous and basal cell skin carcinomas by in
situ hybridization.
MATERIALS AND METHODS
Materials T7 and T3 polymerase, pBluescript KS(+) plasmid vector and
poly(A)quik Oligo dT-columns (Stratagene, CA). RNasin and DNase I
(Promega, WI), K5 autoradiographic emulsion (Ilford, Cheshire, U.K.),
Tissue-Tek from Miles, IN; [35S]UTPS (Amersham, U.K.); dithiothreitol
and restriction endonucleases (Boehringer Mannheim, Germany).
Tissue preparation Routinely processed, formalin-®xed, and paraf®n-
embedded specimens from seven squamous cell carcinomas and seven basal
cell carcinomas were drawn from the tissue bank at the Departments of
Pathology at Gentofte and Herlev Hospitals.
Preparation of RNA probes Fragments of human uPA cDNA and
human uPAR cDNA were used to prepare the following subclones in
pBluescript KS(+): pHUPA10, basepair 32-627 corresponding to the A-
chain of uPA (EMBO database AQC number K03226); pHUR06, basepair
497-1081 corresponding to uPAR domain D2 (from loop 2) and D3.The
speci®city of pHUPA10 for uPA mRNA and pHUR06 for uPAR mRNA
has previously been veri®ed by use of nonoverlapping probes, which gave
identical results in both cases (Pyke et al, 1991). Generation of 35S-UTP
labeled antisense and sense probes from these plasmids by in vitro
transcription using the relevant polymerase (T3 or T7) was performed as
described by Pyke et al (1991). Before transcription the plasmids were
linearized using the following restriction endonucleases: pHUPA10, SpeI
or HindIII; pHUR06, SpeI or EcoRI. All probe preparations including
both sense and antisense probes were adjusted to 2 3 106 cpm per ml.
Probes were stored at ±20°C until use.
In situ hybridization In situ hybridization was performed using the
method described by Pyke et al (1991). Brie¯y, paraf®n sections mounted
on chrome-alum gelatine coated slides were heated to 60°C for 30 min,
deparaf®nized in xylene, and rehydrated. The slides were acid treated in
0.2 mol per l HCl, Proteinase K (5 mg per ml) treated, and subsequently
®xed in 4% paraformaldehyde, followed by dehydration before the
35S-UTP labeled antisense or sense probes were added. The sections
were then incubated overnight at 47°C in a hybridization solution
containing radiolabeled RNA probe (80 pg per ml) in a solution of 50%
deionized formamide, 10% dextran sulfate, tRNA (1 mg per ml), Ficoll 400
(0.02% wt/vol), 0.02% polyvinylpyrrolidone (wt/vol), 0.2% bovine serum
albumin fraction V (wt/vol), 10 mM dithiothreitol (DTT), 0.3 M NaCl,
0.5 mM ethylenediamine tetraacetic acid, 10 mM Tris-Cl, and 10 mM
NaPO4 (pH 6.8). After hybridization, slides were washed twice for 1 h at
50°C in a washing mix similar to the hybridization solution except that
probe, dextran sulfate, DTT, and tRNA were omitted. The sections were
then treated with RNase A (20 mg per ml), dehydrated, and air dried.
Figure 1. uPAR and uPA mRNA in squa-
mous cell skin carcinomas. In situ hybridization
analysis showing uPAR mRNA expression (a, b,
e, and f) and uPA mRNA expression (c) in a squa-
mous cell carcinoma. In (d) a section adjacent to
that in (a) and (b) is hybridized with a control
sense uPAR RNA probe. Sections are stained
with hematoxylin and eosin and are shown in
bright®eld (a, c, and e) or dark®eld (b, d, and f) il-
lumination. Note the expression of uPAR mRNA
in the well-differentiated cancer cells surrounding
keratinized pearls (arrows in a, b, e, and f), and the
abundant expression of uPA mRNA (c) in most of
the cancer cells in an adjacent section (compare a
and c). Scale bars: (a-d) 55 mm; (e, f) 65 mm.
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Autoradiographic emulsion was applied and the sections were developed
after 10±14 d of exposure.
RESULTS
Analysis of archival paraf®n-embedded tissue samples from
cutaneous squamous and basal cell carcinomas by in situ hybridiza-
tion showed uPAR mRNA and uPA mRNA expression in all the
squamous cell carcinomas investigated (seven of seven). In contrast
neither uPAR nor uPA mRNA could be detected in any of the
basal cell carcinomas (seven of seven). The detection of uPAR and
uPA mRNA was done with radiolabeled antisense RNA probes
transcribed from plasmids containing either uPAR or uPA cDNA
fragments, respectively. The corresponding sense RNA probes
were used as a control of the speci®city of these results and all of
these control hybridizations were negative (Fig 1d).
uPAR mRNA is expressed in the cancer cells of squamous cell
skin carcinomas In situ hybridization analysis of the squamous cell
carcinomas showed that the most abundant signal for uPAR mRNA
is in cancer cells located centrally around keratinized pearls in well-
differentiated areas of the lesions (arrows in Fig 1a, b, e, f). In a few
cases weak uPAR mRNA expression was also detected in singly
located cancer cells dispersed among in¯ammatory and stromal
elements. In addition, in four of the specimens, strong uPAR mRNA
expression was detected focally in cancer cells located at the tip of
invading strands of tumor (Fig 2c-f).
In addition to the signal for uPAR mRNA in cancer cells, weak
hybridization was also detected in scattered macrophage-like
stromal cells immediately surrounding the cancer cells or in the
vicinity of the invasive front (results not shown). The hybridization
signal for uPAR mRNA in these stromal cells was always weaker
than that seen in the cancer cells in the same sections. uPAR
mRNA was in some cases also detected in normal keratinocytes
bordering minor ulcerations adjacent to or overlying the malignant
lesions, but otherwise uPAR mRNA was not detected in any cells
distant from the malignant lesions.
uPA mRNA expression in the cancer cells of squamous cell
skin carcinomas In all the squamous cell carcinomas
investigated, uPA mRNA was detected in virtually all of the
cancer cells. The strongest hybridization signal for uPA mRNA was
found in cancer cells located at the invading edge of the tumor
(Fig 1c). A weak hybridization for uPA mRNA was also found in
®broblast-like cells located in the tumor stroma at the border
between normal and malignant tissue (not shown). uPA mRNA
was detected in nonmalignant keratinocytes at ulcerations adjacent
to the tumor, where uPAR mRNA was also found, but otherwise
uPA mRNA was not detected in any cells distant from the
malignant lesions.
uPAR and uPA are coexpressed in cancer cells at the
invasive front Examination of adjacent sections from squamous
cell carcinomas showed that the uPAR mRNA-expressing cancer
cells at the invasive front also express uPA mRNA (Fig 2a-d). This
coexpression of mRNAs for uPA and its receptor was found in all
of the four specimens in which uPAR expression was detected in
the invading cancer cells.
Basal cell skin carcinomas do not express uPAR or uPA
mRNA uPA or uPAR mRNA were not detected in either
cancer cells or stromal cells inside the lesions in any of the seven
basal cell carcinomas (Fig 3). Two of the specimens showed signals
for both uPA and uPAR mRNA in nonmalignant keratinocytes at
the edge of cutaneous ulcerations above the tumor area. In one
specimen uPA and uPAR mRNA were found focally in
in¯ammatory cells beneath the lesion (not shown). uPA or
uPAR mRNA could not be detected in cells in any other
neighboring normal tissue by in situ hybridization analysis.
Figure 2. uPA and uPAR mRNA in the in-
vading cancer cells of a squamous cell skin
carcinoma. In situ hybridization analysis of uPA
mRNA expression (a, b) and uPAR mRNA ex-
pression (c-f) in adjacent sections of a squamous
cell carcinoma. (e), (f) Higher magni®cations of (c)
and (d), respectively. Sections are stained with he-
matoxylin and eosin and are shown in bright®eld
(a, c, e) or dark®eld (b, d, f) illumination. Note the
strong focal expression of both uPA and uPAR
mRNA in the tip of a strand of cancer cells pro-
truding into the surrounding stroma (arrows in a±
d). Scale bars: (a-d) 55 mm; (e, f) 25 mm.
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DISCUSSION
By in situ hybridization we have shown that uPAR mRNA is
expressed in squamous cell carcinomas of the skin. In all the
squamous cell carcinomas investigated the signal for uPAR mRNA
was expressed focally in well-differentiated cancer cells. Further-
more in four out of seven squamous cell carcinomas uPAR mRNA
could also be detected in cancer cells at the edge of invasively
growing strands of the tumors. In accordance with previous reports,
uPA mRNA was found in virtually all neoplastic cells in the
squamous cell carcinomas (Sappino et al, 1991; Miller et al, 1992).
Importantly, hybridization for uPA and uPAR mRNA on adjacent
sections showed simultaneous expression of both these components
in cancer cells located at the edge of invading squamous cell strands.
In contrast to the expression in squamous cell carcinomas, we did
not detect expression of either uPA or uPAR mRNA in any of the
seven basal cell carcinoma specimens we investigated. There are no
previous reports on histologic studies of uPAR expression in either
squamous or basal cell carcinomas. With respect to uPA our
®ndings are in agreement with a study by Sappino et al (1991), who
did not detect uPA mRNA in basal cell carcinomas, but they are in
contrast to a study by Spiers et al (1996) reporting expression of
uPA mRNA in basal cell carcinomas. We do not know the reason
for the discrepancy between the latter study and ours. The direct
comparisons done both by Sappino et al (1991) and in this study do,
however, show that the level of uPA mRNA expression is much
higher in squamous cell carcinomas than in basal cell carcinomas of
the skin. This conclusion is also supported by an immuno-
histochemical study showing the presence of uPA protein in
squamous cell carcinomas but not detectable amounts in basal cell
carcinomas (Miller et al, 1992). Furthermore, in a recent study of
skin tumor extracts by enzyme-linked immunosorbent assay it was
shown that both uPA and uPAR are present at signi®cantly lower
levels in basal cell carcinomas compared with squamous cell
carcinomas and malignant melanomas (Maguire et al, 2000). Both
uPA and uPAR expression thus appears to be much more abundant
in squamous cell carcinomas than in basal cell carcinomas. A
correlation between high expression of both uPA and uPAR in
tumors and their aggressiveness has been demonstrated in several
experimental models of invasive growth (Ossowski et al, 1991;
Crowley et al, 1993; Kook et al, 1994; Shapiro et al, 1996; Kim et al,
1998). On this background we suggest that the higher metastatic
potential of squamous cell carcinomas compared with basal cell
carcinomas may be related to the coexpression of the two
components required for cell surface plasminogen activation in
invading squamous carcinoma cells.
The coexpression of mRNAs for uPA and uPAR in invading
squamous carcinoma cells means that uPA released from the cancer
cells subsequently is bound to the receptor in an autocrine manner.
Assembly of the components required for generation of uPA-
mediated cell surface proteolysis in this way is apparently different
from the situation during invasive growth of colon and breast
cancer. In colon adenocarcinomas both cancer cells and macro-
phages express uPAR, whereas neighboring ®broblast-like cells
express uPA (Grùndahl-Hansen et al, 1991; Pyke et al, 1991, 1994).
In ductal breast carcinomas uPAR is located in tumor-associated
macrophages (Pyke et al, 1993), whereas uPA is expressed by
myo®broblasts or in some rare cases by the cancer cells (Nielsen
et al, 1996). In the last two types of cancer, secreted uPA therefore
binds to uPAR in a paracrine fashion. These observations illustrate
that different cancer types have different expression patterns of the
molecules needed for localized generation of plasmin activity. This
is also the case for the expression of several matrix-degrading
metalloproteases, and there is increasing evidence for similarities in
the pattern of expression of molecules generating or regulating
proteolysis between certain types of cancers and certain tissue
remodeling processes (Johnsen et al, 1998). Examples are ductal
mammary carcinoma and postlactational mammary gland involu-
tion (Lund et al, 1996, 2000; Nielsen et al, 1996), colon
adenocarcinoma and epithelial cell shedding into the gastro-
intestinal tract (Larsson et al, 1984; Pyke et al, 1991), and squamous
cell skin cancer and skin wound healing as discussed below.
The distinctive and simultaneous expression of both uPA and
uPAR mRNA in cancer cells at invasive foci in squamous cell skin
cancer is thus very similar to the expression of uPA and uPAR
mRNA in leading-edge keratinocytes during re-epithelialization of
skin wounds (Grùndahl-Hansen et al, 1988; Rùmer et al, 1991,
1994). Furthermore the matrix metalloproteases interstitial col-
lagenase, stromelysin-1, collagenase-3, and gelatinase B in both
squamous cell skin cancer (Polette et al, 1991; Pyke et al, 1992;
Airola et al, 1997; Tsukifuji et al, 1999) and skin repair (Saarialho-
Kere et al, 1993, 1994; Salo et al, 1994; Madlener et al, 1998; Lund
et al, 1999) are expressed by the epithelial cells, whereas gelatinase A
and stromelysin-3 in both cases are expressed in ®broblastic stromal
cells (Wolf et al, 1992; Pyke et al, 1992; Madlener et al, 1998; Asch
et al, 1999; Lund et al, 1999; Tsukifuji et al, 1999). A crucial
difference between skin repair and malignancy, however, is that the
expression of uPA, uPAR, and the matrix metalloproteases in the
Figure 3. Basal cell skin carcinoma. In situ hy-
bridization analysis of uPAR mRNA expression
(a, b) and uPA mRNA expression (c, d) in adja-
cent sections of a basal cell carcinoma. Sections
are stained with hematoxylin and eosin and are
shown in bright®eld (a, c) or dark®eld (b, d) illu-
mination. There is no hybridization signal for
either uPAR or uPA mRNA in any cancer or
stromal cells, above the background signal seen
with the corresponding sense RNA probes (not
shown). The bright areas seen in the dark®eld mi-
crographs in (b) and (d) are artefacts due to re¯ec-
tions in collagen. Scale bars: 85 mm.
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migrating keratinocytes is downregulated when the skin wound is
healed, whereas a similar downregulation appears to be lacking in
the squamous cell carcinoma cells. This is in accordance with the
proposal by Dvorak, based on observations of stromal±epithelial cell
interactions, that cancer can be considered as wounds that do not
heal (Dvorak, 1986).
Studies on skin wound healing are therefore likely to contribute
to our understanding of squamous cell skin cancer. We recently
found that skin wound repair is severely impaired in mice made
de®cient in plasminogen by targeted gene disruption (Rùmer et al,
1996), and completely arrested when the plasminogen-de®cient
mice were treated with the metalloprotease inhibitor Galardin
(Lund et al, 1999). These results de®nitively prove that both
plasminogen and certain matrix metalloproteases participate in the
restoration of an intact epidermal layer following acute skin injury.
This is probably re¯ecting that keratinocytes in the epithelial
outgrowth use plasmin and certain metalloproteases to proteoly-
tically dissect their way through the extracellular matrix (Bugge et al,
1996; Rùmer et al, 1996; Lund et al, 1999). A similar function of
the plasminogen activation system is likely in squamous skin cancer.
The ability of the squamous cell carcinomas to simultaneously
produce uPA and uPAR may therefore be crucial for their more
aggressive and metastatic behavior. Further support for such a role
of plasminogen activation in metastasis comes from studies showing
that metastasis of experimental mammary tumors is impaired in
plasminogen-de®cient mice (Bugge et al, 1998).
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